Physical Examination — Still Relevant in Sjögren Syndrome

REFERENCES

1. 1.↵
   1. Bynum W

   . The history of medicine: a very short introduction. Oxford: Oxford University Press; 2018:48–52.
2. 2.↵
   1. Shellenberger RA,
   2. Balakrishnan B,
   3. Avula S,
   4. Ebel A,
   5. Shaik S

   . Diagnostic value of the physical examination in patients with dyspnea. Cleve Clin J Med 2017;84:943–50.

   OpenUrl
3. 3.↵
   1. Grayburn PA,
   2. Smith MD,
   3. Handshoe R,
   4. Friedman BJ,
   5. DeMaria AN

   . Detection of aortic insufficiency by standard echocardiography, pulsed Doppler echocardiography, and auscultation. A comparison of accuracies. Ann Intern Med 1986;104:599–605.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Helmick CG,
   2. Felson DT,
   3. Lawrence RC,
   4. Gabriel S,
   5. Hirsch R,
   6. Kwoh CK,
   7. et al.

   Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15–25.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Tzioufas AG,
   2. Kapsogeorgou EK,
   3. Moutsopoulos HM

   . Pathogenesis of Sjogren’s syndrome: what we know and what we should learn. J Autoimmun 2012;39:4–8.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Routsias JG,
   2. Goules JD,
   3. Charalampakis G,
   4. Tzima S,
   5. Papageorgiou A,
   6. Voulgarelis M

   . Malignant lymphoma in primary Sjogren’s syndrome: an update on the pathogenesis and treatment. Seminar Arthritis Rheum 2013;43:178–86.

   OpenUrl
7. 7.↵
   1. Papageorgiou A,
   2. Voulgarelis M,
   3. Tzioufas AG

   . Clinical picture, outcome and predictive factors of lymphoma in Sjogren syndrome. Autoimmun Rev 2015;14:641–9.

   OpenUrl
8. 8.↵
   1. Chiu YH,
   2. Chung CH,
   3. Lin KT,
   4. Lin CS,
   5. Chen JH,
   6. Chen HC,
   7. et al.

   Predictable biomarkers of developing lymphoma in patients with Sjogren syndrome: a nationwide population-based cohort study. Oncotarget 2017;8:50098–108.

   OpenUrl
9. 9.↵
   1. Ekström Smedby K,
   2. Vajdic CM,
   3. Falster M,
   4. Engels EA,
   5. Martinez-Maza O,
   6. Turner J,
   7. et al.

   Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029–38.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Zampeli E,
    2. Kalogirou EM,
    3. Piperi E,
    4. Mavragani CP,
    5. Moutsopoulos HM

    . Tongue atrophy in Sjögren syndrome patients with mucosa-associated lymphoid tissue lymphoma: autoimmune epithelitis beyond the epithelial cells of salivary glands? J Rheumatol 2018;45:1565–71.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Rasmussen A,
    2. Ice JA,
    3. Li H,
    4. Grundahl K,
    5. Kelly JA,
    6. Radfar L,
    7. et al.

    Comparison of the American-European Consensus Group Sjogren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 2014;73:31–8.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Giannouli S,
    2. Voulgarelis M

    . Predicting progression to lymphoma in Sjogren’s syndrome patients. Expert Rev Clin Immunol 2014;10:501–12.

    OpenUrl
13. 13.
    1. Nishishinya MB,
    2. Pereda CA,
    3. Munoz-Fernandez S,
    4. Pego-Reigosa JM,
    5. Rua-Figueroa I,
    6. Andreu JL,
    7. et al.

    Identification of lymphoma predictors in patients with primary Sjogren’s syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015;35:17–26.

    OpenUrlCrossRefPubMed
14. 14.
    1. Nocturne G,
    2. Virone A,
    3. Ng WF,
    4. Le Guern V,
    5. Hachulla E,
    6. Cornec D,
    7. et al.

    Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren’s syndrome. Arthritis Rheumatol 2016;68:977–85.

    OpenUrl
15. 15.
    1. Quartuccio L,
    2. Baldini C,
    3. Bartoloni E,
    4. Priori R,
    5. Carubbi F,
    6. Corazza L,
    7. et al.

    Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev 2015;14:1019–22.

    OpenUrlCrossRefPubMed
16. 16.
    1. Quartuccio L,
    2. Isola M,
    3. Baldini C,
    4. Priori R,
    5. Bartoloni Bocci E,
    6. Carubbi F,
    7. et al.

    Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2014;51:75–80.

    OpenUrlCrossRefPubMed
17. 17.
    1. Tomi AL,
    2. Belkhir R,
    3. Nocturne G,
    4. Desmoulins F,
    5. Berge E,
    6. Pavy S,
    7. et al.

    Brief report: monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjogren’s syndrome. Arthritis Rheumatol 2016;68:1245–50.

    OpenUrl
18. 18.↵
    1. Baimpa E,
    2. Dahabreh IJ,
    3. Voulgarelis M,
    4. Moutsopoulos HM

    . Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine 2009;88:284–93.

    OpenUrlCrossRefPubMed